Regeneron Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: REGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Regeneron Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Regeneron Pharmaceuticals generated $813.0 million of operating cash flow and spent $240.2 million on capital expenditures. That left free cash flow of $572.8 million, a free-cash-flow margin of 13.3% of revenue. Free cash flow was down 38.1% from the prior year's $925.4 million.
Regeneron Pharmaceuticals returned $1.27 billion to shareholders: $96.8 million in dividends and $1.17 billion in share repurchases, equal to 221% of free cash flow. Free cash flow covered dividend payments 5.9 times.
Summary generated from market data by MetaCap's automated system. Methodology
Regeneron Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 1.30B | 727.20M | 844.60M | 1.46B | 1.39B | 808.70M | 917.70M | 1.34B | 1.43B | 722.00M | 1.16B | 1.01B |
| Net Income growth (YoY) | -6.81% | -10.08% | -7.97% | +8.91% | -2.84% | +12.01% | -20.86% | +33.02% | +47.90% | -11.71% | -3.13% | -23.40% |
| Depreciation & Amortization | 123.70M | 123.20M | 145.00M | 136.70M | 135.10M | 126.90M | 126.40M | 121.70M | 120.70M | 114.10M | 113.00M | 105.40M |
| Stock-Based Compensation | 243.00M | 257.40M | 249.30M | 237.00M | 251.70M | 255.70M | 304.40M | 225.10M | 223.20M | 230.10M | 240.40M | 203.90M |
| Change in Working Capital | -649.20M | 36.50M | 5.90M | 625.00M | -227.90M | 129.60M | -86.40M | -63.90M | -908.50M | 440.50M | -61.40M | -192.30M |
| Operating Cash Flow | 813.00M | 1.08B | 1.17B | 1.62B | 1.14B | 1.05B | 1.26B | 1.29B | 354.00M | 1.51B | 1.09B | 1.11B |
| Capital Expenditures | -240.20M | -230.60M | -248.70M | -201.40M | -219.00M | -229.30M | -199.60M | -241.90M | -180.50M | -133.90M | -251.40M | -176.00M |
| Investing Cash Flow | -92.70M | -428.90M | 220.30M | -402.90M | -1.09B | 647.50M | 350.60M | -574.40M | -557.20M | -1.69B | -66.20M | -496.30M |
| Dividends Paid | -96.80M | -97.80M | -92.70M | -91.20M | -92.60M | -93.80M | 0 | 0 | 0 | 0 | — | — |
| Share Repurchases | -1.17B | -794.30M | -671.70M | -664.00M | -1.06B | -1.04B | -973.00M | -735.10M | -603.90M | -291.30M | -289.00M | -546.50M |
| Financing Cash Flow | -1.22B | -802.20M | -780.10M | -717.90M | -1.13B | -1.09B | -1.14B | -634.00M | -478.10M | 47.10M | -446.10M | -407.30M |
| Net Change in Cash | -504.60M | -153.10M | 610.60M | 497.50M | -1.08B | 604.00M | 477.20M | 83.60M | -681.60M | -128.00M | 577.60M | 210.50M |
| Free Cash Flow | 572.80M | 848.30M | 922.00M | 1.42B | 925.40M | 815.80M | 1.06B | 1.05B | 173.50M | 1.38B | 838.30M | 938.30M |
This table shows 12 quarterly periods of Regeneron Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow REGN's reporting calendar. What is a cash flow statement?